15 March 2014

Publications resulting from the NCU grant 2013 (Publications only)

A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate and colorectal cancer.

Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A, Aaltonen L, Leminen A, Heikkilä P, Blomqvist C, Bützow R, Aittomäki K, Nevanlinna H. J Med Genet 49: 439-432, 2012 
 
Screening of Finnish RAD51C Founder Mutations in Prostate and Colorectal Cancer Patients 
Pelttari LM, Nurminen R, Gylfe A, Aaltonen LA, Schleutker J, Nevanlinna H.. BMC Cancer 12:552, 2012 
 
Exome Sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
Kiiski JI, Pelttari LM, Khan S, Freysteinsdottir ES, Reynisdottir I, Hart SN, Shimelis H, Vilske S, Kallioniemi A, Schleutker J, Leminen A, Bützow R, Blomqvist C, Barkardottir RB, Couch FJ, Aittomäki K, Nevanlinna H. Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15172-7. doi: 
 
Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. 
Lehtinen M, Apter D, Baussano I, Eriksson T, Natunen K, Paavonen J, Vänskä S, Bi D, David MP, Datta S, Struyf F, Jenkins D, Pukkala E, Garnett G, Dubin G.Vaccine. 2015 Mar 3;33(10):1284-90. doi: 10.1016/j.vaccine.2014.12.019.
 
Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study. 
Namujju PB, Pajunen E, Simen-Kapeu A, Hedman L, Merikukka M, Surcel HM, Kirnbauer R, Apter D, Paavonen J, Hedman K, Lehtinen M.BMC Res Notes. 2014 Jul 11;7:445. doi: 10.1186/1756-0500-7-445.

Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. 
Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmerón J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Peters K, Tjalma WA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L. J Infect Dis. 2014 Aug 15;210(4):517-34. doi: 10.1093/infdis/jiu139.

Cervical cancer screening in Europe: Quality assurance and organisation of programmes. 
Elfström KM, Arnheim-Dahlström L, von Karsa L, Dillner J. Eur J Cancer. 2015 Mar 25. pii: S0959-8049(15)00224-5. doi: 10.1016/j.ejca.2015.03.008. 

Organization and quality of HPV vaccination programs in Europe. 
Elfström KM, Dillner J, Arnheim-Dahlström L. Vaccine. 2015 Mar 30;33(14):1673-81. doi: 10.1016/j.vaccine.2015.02.028.
 
International standardization and classification of human papillomavirus types. 
Bzhalava D, Eklund C, Dillner J. Virology. 2015 Feb;476:341-4. doi: 10.1016/j.virol.2014.12.028.

Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. 
Eklund C, Forslund O, Wallin KL, Dillner J. J Clin Microbiol. 2014 Feb;52(2):449-59. doi: 10.1128/JCM.02453-13.  

Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. 
Söderlund-Strand A, Uhnoo I, Dillner J. Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2757-64. doi: 10.1158/1055-9965.EPI-14-0687. 
 
Evaluation of human papillomavirus DNA detection in samples obtained for routine Chlamydia trachomatis screening. Söderlund-Strand A, Wikström A, Dillner J. J Clin Virol. 2015 Mar;64:88-91. doi: 10.1016/j.jcv.2015.01.008. 

Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial. 
Smelov V, Elfström KM, Johansson AL, Eklund C, Naucler P, Arnheim-Dahlström L, Dillner J. Int J Cancer. 2015 Mar 1;136(5):1171-80. doi: 10.1002/ijc.29085. 

Long-term HPV type-specific risks for ASCUS and LSIL: a 14-year follow-up of a randomized primary HPV screening trial. Elfström KM, Smelov V, Johansson AL, Eklund C, Naucler P, Arnheim-Dahlström L, Dillner J. Int J Cancer. 2015 Jan 15;136(2):350-9. doi: 10.1002/ijc.28984. 

The Process of Moving from a Regionally Based Cervical Cytology Biobank to a National Infrastructure. 
Perskvist N, Norlin L, Dillner J. Biopreserv Biobank. 2015 Jan 19. 

A complex intervention for workflow enhancement at the Swedish cervical cytology biobank. 
Perskvist N, Björklund C, Dillner J. Biopreserv Biobank. 2014 Feb;12(1):69-73. doi: 10.1089/bio.2013.0068. 

Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. 
Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, Netterlid E, Sparén P, Arnheim-Dahlström L. JAMA. 2014 Feb 12;311(6):597-603. doi: 10.1001/jama.2014.95.

Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. 
Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw KL, Dasbach EJ, Kjær SK. PLoS One. 2014 Feb 5;9(2):e88323. doi: 10.1371/journal.pone.0088323. 

Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Baussano I, Dillner J, Lazzarato F, Ronco G, Franceschi S. Infect Agent Cancer. 2014 Jan 20;9(1):4. doi: 10.1186/1750-9378-9-4.

Are 20 human papillomavirus types causing cervical cancer? 
Arbyn M, Tommasino M, Depuydt C, Dillner J. J Pathol. 2014 Dec;234(4):431-5. doi: 10.1002/path.4424

Translational cancer research: balancing prevention and treatment to combat cancer globally. 
Wild CP, Bucher JR, de Jong BW, Dillner J, von Gertten C, Groopman JD, Herceg Z, Holmes E, Holmila R, Olsen JH, Ringborg U, Scalbert A, Shibata T, Smith MT, Ulrich C, Vineis P, McLaughlin J. J Natl Cancer Inst. 2014 Dec 16;107(1):353. doi: 10.1093/jnci/dju353. 

Two new loci and gene sets related to sex determination and cancer progression are associated with susceptibility to testicular germ cell tumour. 
Kristiansen W, Karlsson R, Rounge T, Whitington T, Andreassen BK, Magnusson PK, Fosså SD, Adami H-O, Turnbull C, Haugen TB, Grotmol T, Wiklund F. 
Hum Mol Genet. 2015 Jul 15;24(14):4138-46. doi: 10.1093/hmg/ddv129. Epub 2015 Apr 15
 
Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome, 5q31.1 predict outcome in AML. 
Treppendahl MB, Qiu X, Søgaard A, Yang X, Nandrup-Bus C, Hother C, Andersen MK, Kjeldsen L, Möllgaard L, Hellström-Lindberg E, Jendholm J, Porse BT, Jones PA, Liang G, Grønbæk K. Blood. 2012;119(1):206-16.
 
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. 
Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, Della Porta, MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M. 
Blood. 2013 Oct 24;122(17):2943-64.
 
Limited clinical efficacy of azacitidine in transfusiondependent, growth factor resistent, low and INT-1 risk MDS. Results from the Nordic NMDSG08A clinical Phase 2 trial. 
Tobiasson M, Dybedahl I, Skov Holm M, Karimi M, Brandefors L, Garelius H, Grövdal M, Høgh Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Olsnes A, Porwit A, Saft L, Möllgård L, Hellström-Lindberg E.. Blood Cancer J. 2014 Mar 7;4:e189.
 
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).. 
Saft L, Karimi M, Ghaderi M, Matolscy A, Fenaux P, Mufti G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backstrom J, MacBeth K, Hellström-Lindberg E. Haematologica. 2014 Jun;99(6):1041-9. 4
 
A pilot phase I dose finding safety study of the thrombopoietinreceptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SEJ, Hellström- Lindberg E, Cherif H. Eur J Haematol. 2014 Nov;93(5):439-45.
 
High throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.
Karimi M, Nilsson C, Dimitriou M, Jansson M, Matsson H, Unneberg P, Lehmann S, Kere J, Hellström-Lindberg E. Haematologica. 2015 Mar 13. pii: haematol.2014.118034.
 
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, Elena C, Gallì A, Walldin G, Della Porta MG, Raaschou-Jensen K, Travaglino E, Kallenbach K, Pietra D, Ljungström V, Conte S, Boveri E, Invernizzi R, Rosenquist R, Campbell PJ, Cazzola M, Hellström-Lindberg E. Blood. 2015 May 8. pii: blood-2015-03-633537. [Epub ahead of print].
 
 
Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis.
Andersen JP, Bøgsted M, Dybkær K, Mellqvist UH, Morgan GJ, Goldschmidt H, Dimopoulos MA, Einsele H, San Miguel J, Palumbo A, Sonneveld P, Johnsen HE. PLoS One. 2015 Jan 28;10(1):e0116966. 

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, et al. Lancet Oncol. 2014 Nov;15(12):e538-48. doi:10.1016/S1470-2045(14)70442-5. Review. 

Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma 
Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, et al. (2013). PLoS One 8: e83252. Available: http://dx.plos.org/10.1371/journal.pone.0083252. Accessed 2 January 2014. 

Stable phenotype of B-cell subsets following cryopreservation and thawing of human lymphocytes stored in a tissue biobank.
Rasmussen SM, Bilgrau AE, Schmitz A, Falgreen S, Bergkvist KS, et al. (2014) Submitted Cytometry B Clin Cytom. 

Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man.
Bergkvist KS, Nyegaard M, Bøgsted M, Schmitz A, Bødker JS, et al. (2014) BMC Immunol 15: 3. Available: http://www.biomedcentral.com/1471-2172/15/3. Accessed 7 
 
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.
Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358. PubMed PMID: 24497560; PubMed Central PMCID: PMC3912952. 

Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy 
Johnsen HE, Bergkvist KS, Schmitz A, Kjeldsen MK, Hansen SM, Gaihede M, Nørgaard MA, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Bødker JS, Bøgsted M, Dybkær K; for the Myeloma Stem Cell Network (Mscnet).. Leuk Lymphoma. 2013 Nov 1. [Epub ahead of print] PubMed PMID:23998255. 

Quality Assessment of Haematopoietic Stem Cell Grafting Committee of European Blood and Marrow Transplantation Society. Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. 
Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, Spedini P, Fiamenghi C, Cuneo A, Knopińska W, Swierkowska-Czeneszew M, Petriz J, Fruehauf S, Farge D, Mohty M, Passweg J, Ruuto T, Madrigal A, Johnsen HE; Biol Blood Marrow Transplant. 2013 Dec;19(12):1670-6. doi: 10.1016/j.bbmt.2013.08.005. Epub 2013 Aug 27. PubMed PMID: 23988403. 

Performance comparison of Affymetrix SNP6.0 and cytogenetic 2.7M whole-genome microarrays in complex cancer samples 
Bødker JS, Gyrup C, Johansen P, Schmitz A, Madsen J, Johnsen HE, Bøgsted M, Dybkær K, Nyegaard M.. Cytogenet Genome Res. 2013;139(2):80-7. doi: 10.1159/000345125. Epub 2012 Nov 20. PubMed PMID: 23182917. 

A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells 
Kloster MB, Bilgrau AE, Rodrigo-Domingo M, Bergkvist KS, Schmitz A, Sønderkær M, Bødker JS, Falgreen S, Nyegaard M, Johnsen HE, Nielsen KL, Dybkaer K, Bøgsted M.. BMC Genomics. 2012 Nov 5;13:596. doi: 10.1186/1471-2164-13-596. PubMed PMID: 23127183; PubMed Central PMCID: PMC3505742. 

Cancer stem cell definitions and terminology: the devil is in the details. 
Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. Nat Rev Cancer. 2012 Nov;12(11):767-75. doi: 1038/nrc3368. Epub 2012 Oct 11. PubMed PMID: 23051844. 
 
European Myeloma Network. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. 
Ross FM, Avet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O'Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Hodkinson C, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michau L, Neben K, Hermansen NE, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE; Haematologica. 2012 Aug;97(8):1272-7. Epub 2012 Feb 27. PubMed PMID: 22371180; PubMed Central PMCID: PMC3409827. 
 
A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. 
Wadt KA, Aoude LG, Johansson P, Solinas A, Pritchard A, Crainic O, Andersen, MT, Kiilgaard JF, Heegaard S, Sunde L, Federspiel B, Madore J, Thompson JF, McCarthy SW, Goodwin A, Tsao H, Jönsson G, Busam K, Gupta R, Trent JM, Gerdes AM, Brown KM, Scolyer RA, Hayward NK. Clin Genet. 2014 Sep 15
 
Molecular characterization of melanoma cases in denmark suspected of genetic predisposition. 
Wadt KA, Aoude LG, Krogh L, Sunde L, Bojesen A, Grønskov K, Wartacz N, Ek J, Tolstrup-Andersen, M, Klarskov-Andersen M, Borg Å, Heegaard S, Kiilgaard, JF, Hansen TV, Klein K, Jönsson G, Drzewiecki KT, Dunø M, Hayward NK, Gerdes AM. PLoS One. 2015 Mar 24;10(3):e0122662
 
Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. 
Aoude LG, Pritchard AL, Robles-Espinoza CD, Wadt K, Harland M, Choi J, Gartside M, Quesada V, Johansson P, Palmer JM, Ramsay AJ, Zhang X, Jones, K, Symmons J, Holland EA, Schmid H, Bonazzi V, Woods S, Dutton-Regester K, Stark MS, Snowden H, van Doorn R, Montgomery GW, Martin NG, Keane TM, López-Otín C, Gerdes AM, Olsson H, Ingvar C, Borg A, Gruis NA, Trent JM, Jönsson, G, Bishop DT, Mann GJ, Newton-Bishop JA, Brown KM, Adams DJ, Hayward NK. J Natl Cancer Inst. 2014 Dec 13;107(2)
 
Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass. 
Staaf J, Harbst K, Lauss M, Ringnér M, Måsbäck A, Howlin J, Jirström K, Harland M, Zebary A, Palmer JM, Ingvar C, Olsson H, Newton-Bishop J, Hansson J, Hayward N, Gruis N, Jönsson G; Melanoma Genetics Consortium. J Invest Dermatol. 2014 Dec;134(12):3000-3
 
Causes and risk factors for mortality within 1 year after obesity surgery in a population-based cohort study 
Tao W, Östlund M, Lu Y, Mattsson F, Lagergren J. Surg Obes Rel Dis 2015 Mar-Apr 11(2):399-405

Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary nonpolyposis colorectal carcinoma without DNA mismatch repair deficiency.
Nieminen TT, O’Donohue M-F, Wu Y, Lohi H, Scherer SW, Paterson AD, Ellonen P, Abdel-Rahman WM, Valo S, Mecklin J-P, Järvinen HJ, Gleizes P-E, Peltomäki P.. Gastroenterology 147: 595-598 (2014).

Promoter-specific alterations of APC are a rare cause for mutation-negative familial adenomatous polyposis. 
Pavicic W, Nieminen T, Gylling A, Pursiheimo J-P, Laiho A, Gyenesei A, Järvinen HJ, Peltomäki P. Genes Chrom Cancer 53: 857-864 (2014).

Epigenetic mechanisms in the pathogenesis of Lynch syndrome 
Peltomäki P.. Clin Genet 85: 403 – 412 (2014).

Occupation and scrotal cancer: Results of the NOCCA study. 
Verhoeven, R.H.A., Kiemeney, L.A.L.M., Coebergh, J.W.W., Weiderpass, E., Kjaerheim, K., Martinsen, J.I., Lynge, E., Pukkala, E. (Acta Oncol. 2011; 50: 1244-1246).

Occupation and risk of primary Fallopian tube carcinoma in Nordic countries.
Riska, A., Martinsen, J.I., Kjaerheim, K., Lynge, E., Sparen, P., Tryggvadottir, L., Weiderpass, E., Pukkala, E. (Int. J. Cancer 2012; 131: 186–192).

Cancer incidence among priests – 45 years of follow-up in four Nordic countries. 
Stang, A., Martinsen, J.I., Kjaerheim, K., Weiderpass, E., Sparén, P., Tryggvadóttir, L., Pukkala, E. (Eur. J. Epidemiol. 2012; 27: 101-108).

Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: Results from NORDCAN and NOCCA databases. 
Koivisto-Korander R., Martinsen J.I., Weiderpass E., Leminen A., Pukkala, E. (Maturitas 2012; 72: 56-60).

Occupational exposure to wood dust and formaldehyde and risk of nasal, nasopharyngeal, and lung cancer among Finnish men. 
Siew SS, Kauppinen T, Kyyrönen P, Heikkilä P, Pukkala E. (Cancer Manag. Res. 2012;4:223-232). 

Occupation and leukaemia in Nordic countries. 
Talibov, M., Kautiainen, S., Martinsen, J.I., Kjaerheim, K., Lynge, E., Sparen, P., Tryggvadottir, L., Weiderpass, E., Pukkala, E. J. Occup. (Environ. Med. 2012; 54: 1527-1532).

Cholangiocarcinoma among workers in the printing industry: Using the NOCCA database to elucidate the generalisability of a cluster report from Japan. 
Vlaanderen, J., Straif, K., Martinsen, J.I., Kauppinen, T., Pukkala, E., Sparen, P., Tryggvadottir, L., Weiderpass, E. Kjærheim, K. (Occup. Environ. Med. 2013; 70: 828-30. doi: 10.1136/oemed-2013-101500).

Occupational exposure to trichloroethylene and perchloroethylene and the risk of lymphoma, liver, and kidney cancer in four Nordic countries. 
Vlaanderen, J., Straif, K., Pukkala, E., Kauppinen, T., Kyyrönen, P., Martinsen, J.I., Kjærheim, K., Tryggvadottir, L., Hansen, J., Sparen, P., Weiderpass, E. (Occup. Environ. Med. 2013; 70: 393-401). 

Performance of the Finnish Information System on Occupational Exposure (FINJEM) in epidemiologic, surveillance and other applications. 
Kauppinen, T., Uuksulainen, S., Saalo, A., Mäkinen, I., Pukkala, E. (Ann. Occup. Hyg. 2014; 58: 380-396; doi:10.1093/annhyg/met074).

Tetrachloroethylene exposure and bladder cancer risk: A meta-analysis of dry cleaning worker studies.
Vlaanderen, J., Straif, K., Ruder, A., Blair, A., Hansen, J., Lynge, E., Charbotel, B., Loomis, D., Kauppinen, T., Kyyrönen, P., Martinsen, J.I., Pukkala, E., Weiderpass, E., Guha, N. (Environ. Hlth Perpect. 2014; 122: 661-666).

Cancer incidence among firefighters – 45 years of follow-up in five Nordic countries. 
Pukkala, E., Martinsen, J.I., Weiderpass, E., Kjaerheim, K., Lynge, E., Tryggvadottir, L., Sparén, P., Demers, P. (Occup. Environ. Med. 2014; 71: 398-404; doi:10.1136/oemed-2013-101803).

Occupational exposure to solvents and acute myeloid leukemia: a population-based case-control study in Nordic countries. 
Talibov, M., Kautiainen, S., Martinsen, J.I., Kjaerheim, K., Lynge, E., Sparen, P., Weiderpass, E., Tryggvadottir, L., Kauppinen, T., Kyyrönen, P., Pukkala, E. (Scand. J. Work Environ. Health 2014; 40: 511-517; doi: 10.5271/sjweh.3436). 

Occupation and risk of oesophageal adenocarcinoma and squamous-cell carcinoma: the Nordic Occupational Cancer study. 
Jansson, C., Oh, J.-K., Martinsen, J.I., Lagergren, J., Plato, N., Kjaerheim, K., Pukkala, E., Sparén, P., Tryggvadottir, L., Weiderpass, E. (Int. J. Cancer in press, accepted November 2014).
Cancer incidence in a cohort with high fish consumption. 
Turunen, A.W., Suominen, A.L., Kiviranta, H., Verkasalo, P.K., Pukkala, E. (Cancer Causes Control 2014; 25: 1595-1602; doi 10.1007/s10552-014-0464-5).
 
Cancer incidence among waiters ─ 45 years of follow-up in five Nordic countries. 
Reijula, J., Kjaerheim, K., Lynge, E.,  Martinsen, J.I., Reijula, K., Sparén, P., Tryggvadottir, L. Weiderpass, E., Pukkala, E. (Scand. J. Public Health 2015; 43: 204–211).
 
Occupational exposure to extremely low frequency magnetic fields and electrical shocks and acute myeloid leukemia in four Nordic countries. 
Talibov, M., Guxens, M., Pukkala, E., Huss, A., Kromhout, H., Slottje, P., Martinsen, J.I., Kjaerheim, K., Sparén, P., Weiderpass, E., Tryggvadottir, L., Uuksulainen, S., Vermeulen, R. (Submitted to Cancer Cause Control, January 2015).
 
Testicular germ cell tumours and parental occupational exposure to pesticides: a register-based case-control study in Denmark, Finland, Norway and Sweden (NORD-TEST study). 
Le Cornet, C., Fervers, B., Dalton, S.O., Feychting, M., Pukkala, E., Tynes, T., Hansen, J., Beranger, R., Kauppinen, T., Uuksulainen, S., Wiebert, P., Woldbæk, T., Skakkebæk, N.E., Olsson, A., Schüz, J.  (Submitted to Occup. Environ. Med., January 2015).
 
Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia
Vang SI, Schmiegelow K, Frandsen T.L, Rosthøj, S, Nersting, J. Cancer Chemotherapy and Pharmacology 2015 May;75(5):1089-93.

Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M, Rosthøj S, Nygaard U, Heldrup J, Harila-Saari A, Jonsson OG, Bechensteen AG, Abrahamsson J, Lausen B, Frandsen TL, Weinshilboum RM, Schmiegelow K. Cancer Chemother Pharmacol. 2015 Jan;75(1):59-66.

Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance, Therapy of Childhood ALL: Hypothesis and Case Report.
Nielsen SN, Frandsen TL, Nersting J, Hjalgrim LL, Schmiegelow K., J Pediatr Hematol Oncol. 2014 Aug 28. [Epub ahead of print] PMID: 25171455.

Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. J Pediatr Hematol Oncol. 2014 Oct;36(7):503-17. 

Nordic Society of Paediatric Haematology, Oncology. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer. 
Levinsen M, Rotevatn EØ, Rosthøj S, Nersting J, Abrahamsson J, Appell ML, Bergan S, Bechensteen AG, Harila-Saari A, Heyman M, Jonsson OG, Maxild JB, Niemi  M, Söderhäll S, Schmiegelow K; Pediatr Blood Cancer. 2014 May;61(5):797-802.

Host genome variations and risk of infections during induction treatment for childhood acute lymphoblastic leukaemia. 
Lund B, Wesolowska-Andersen A, Lausen B, Borst L, Rasmussen KK, Müller K, Klungland H, Gupta R, Schmiegelow K. Eur J Haematol. 2014 Apr;92(4):321-30.

Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. 
Frandsen TL, Heyman M, Abrahamsson J, Vettenranta K, Åsberg A, Vaitkeviciene, G, Pruunsild K, Toft N, Birgens H, Hallböök H, Quist-Paulsen P, Griškevičius L, Helt L, Hansen BV, Schmiegelow K. Eur J Cancer. 2014 Jan;50(2):251-9.

Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.
Schmiegelow K, Levinsen MF, Attarbaschi A, Baruchel A, Devidas M, Escherich G, Gibson B, Heydrich C, Horibe K, Ishida Y, Liang DC, Locatelli F, Michel G, Pieters R, Piette C, Pui CH, Raimondi S, Silverman L, Stanulla M, Stark B, Winick N, Valsecchi MG. J Clin Oncol. 2013 Jul 1;31(19):2469-76.

Can SLC19A1 80G>A polymorphisms predict risk of extremely delayed MTX excretion after high dose of methotrexate?
Rasmussen MM, Christensen RH, Gregers J, Heldrup J, Nersting J, Schmiegelow K. J Pediatr Hematol Oncol. 2013 Jul;35(5):417-8.

Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes. 
Ebbesen MS, Nersting J, Jacobsen JH, Frandsen TL, Vettenranta K, Abramsson J,  Wesenberg F, Schmiegelow KJ Clin Pharmacol. 2013 Jun;53(6):670-4.

The Finnish prostate cancer screening trial: Analyses on the screening failures. 
Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A. Int J Cancer. 2014 Oct 30. doi: 10.1002/ijc.29300. [Epub ahead of print]
 
Family history in the Finnish prostate cancer screening trial.
Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J, Auvinen A. Int J Cancer. 136(9):2172-7, 2014.
 
Genome-wide association study of prostate cancer-specific survival. Cancer Epidemiol Biomarkers
Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, FitzGerald LM, Henderson BE, Schumacher FR, Haiman CA, Sipeky C, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubiński J, Kluźniak W, Cannon-Albright L, Brenner H, Herrmann V, Holleczek B, Park JY, Sellers TA, Lim HY, Slavov C, Kaneva RP, Mitev VI, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A; PRACTICAL consortium, Batra J, Clements JA; Australian Prostate Cancer BioResource, Albanes D, Andriole GL, Berndt SI, Chanock S, Gapstur SM, Giovannucci EL, Hunter DJ, Kraft P, Le Marchand L, Ma J, Mondul AM, Penney KL, Stampfer MJ, Stevens VL, Weinstein SJ, Trichopoulou A, Bueno-de-Mesquita BH, Tjønneland A, Cox DG; BPC3 consortium, Maehle L, Schleutker J, Lindström S, Wiklund F. Prev. 2015 Nov;24(11):1796-800.


Go Back

Share